LAMTOR5

Across TCGA pan-cancer cohorts, LAMTOR5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LAMTOR5 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LAMTOR5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LAMTOR5 expression acts as an unfavorable survival marker.

LUAD, CCRCC, and PDAC are the cancer types where LAMTOR5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.755	0.996	.002	15	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.830	.038	3	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LAMTOR5–LUAD (DFS)

Open the LUAD breakdown →